CPT® (CDT codes and descriptions are copyright American Dental Association) | |
---|---|
86900 | |
Z94.0 | Kidney transplant status |
Z94.4 | Liver transplant status |
ICD-9-CM |
This amino acid change results in a JAK2 protein that is constantly "on," leading to uncontrolled blood cell production. Other mutations in the JAK2 gene are also associated with MPNs.
A positive JAK2 V617F mutation test, along with other supporting clinical signs, means it is likely that the person tested has an MPN. Other testing, such as a bone marrow biopsy, may need to be performed to determine which MPN the person has and to evaluate its severity.
The primary genetic test for JAK2 mutations that lead to MPNs is JAK2 V617F, named for a mutation at a specific location in the JAK2 gene. It is typically ordered first. If it is negative, then tests for other mutations in the JAK2 gene that are also associated with MPNs, such as JAK2 exon 12, may be used to help make a diagnosis.
Other mutations that may occur in the JAK2 gene will not be detected. In vitro studies have indicated that this assay has an analytical sensitivity of 1%. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
In JAK2, this kind of mutation, called a point mutation, replaces the normal amino acid valine (abbreviated V) with phenylalanine (abbreviated F). This amino acid change results in a JAK2 protein that is constantly “on,” leading to uncontrolled blood cell production.
JAK2 mutations are rare in de novo acute myeloid leukemia (AML), and JAK2-mutated acute myeloid leukemia (AML) patients usually have a previous history of myeloproliferative neoplasms (MPNs).
Mutations in this gene result in constant increased blood cell production. Depending on which cells are stimulated by a JAK2 mutation, one of several types of myeloproliferative disorders can develop, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
For laboratories performing next generation sequencing (NGS or "hotspot") testing platforms: Molecular testing for BCR-ABL, JAK 2, JAK, exon 12, and CALR/MPL genes by NGS is covered as medically necessary for the identification of myeloproliferative disorders.
CPT Codes*: JAK2 V617F Only: 81270 JAK2 V617F and EXON 12-14 run concurrently or by reflex: 81270, 81403.
The JAK2 Wild Type Reference Standard is a highly-characterized, biologically-relevant quality control material used to assess the performance of assays that detect somatic mutations, such as Sanger and qPCR sequencing assays.
1.
[4] According to the World Health Organization, essential thrombocytosis is a disease that occurs when the platelet count is more than 450000 with the presence of Janus kinase 2 (JAK2), Calreticulin (CALR) or myeloproliferative leukemia virus oncogene (MPL) mutation, lacking clonal or reactive causes.
Rather than being inherited, JAK2 V617F mutations are acquired, occurring at random. As they occur in cells that do not produce eggs or sperm, the mutation is not passed on to a person's children.
CPT® 81206, Under Genetic Analysis Procedures The Current Procedural Terminology (CPT®) code 81206 as maintained by American Medical Association, is a medical procedural code under the range - Genetic Analysis Procedures.
HMO, PPO, Individual Marketplace, & Elite/ProMedica Medicare Plan MTHFR (methyltetrahydrofolate reductase) gene testing (81291) is non-covered. Advantage Genetic testing for hereditary thrombophilia (81291) requires prior authorization.
Unlisted Molecular Pathology - CPT Code 81479 However, when reporting CPT code 81479, the specific gene being tested must be entered in block 80 (Part A for the UBO4 claim), box 19 (Part B for a paper claim) or electronic equivalent of the claim.